Hepion Pharmaceuticals Inc SEC Filings

HEPA OTC

Welcome to our dedicated page for Hepion Pharmaceuticals SEC filings (Ticker: HEPA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Tracking how a clinical-stage biotech funds multi-phase liver trials and measures drug safety can feel like decoding a lab notebook. Hepion Pharmaceuticals’ disclosures mix capital-raise S-3s, trial-update 8-Ks, and an R&D-heavy 10-K in language only auditors enjoy. If you’ve ever typed “Hepion Pharmaceuticals quarterly earnings report 10-Q filing” or hunted for dilution math hidden in footnotes, you know the struggle. This page delivers Hepion Pharmaceuticals SEC filings explained simply, in one feed.

Stock Titan’s AI reads every paragraph so you don’t have to. Our platform turns dense tables into plain-English insights, highlighting cash runway, clinical milestone timing, and risk-factor changes in seconds. With understanding Hepion Pharmaceuticals SEC documents with AI, you’ll see real-time alerts the moment a Form 8-K material event is posted or a shelf registration drops. Drill straight into trial spend trends, patent status shifts, or going-concern language—without paging through hundreds of sections. Interactive dashboards surface segment disclosures, tax credits, and share-count movements, while side-by-side comparisons let you benchmark quarters quickly. You can even export the data to Excel for deeper modeling or set mobile alerts for any new clinical milestone.

For deeper dives, explore:

Hepion Pharmaceuticals annual report 10-K simplified—spot year-over-year R&D and cyclophilin inhibitor progress.
Hepion Pharmaceuticals insider trading Form 4 transactions plus Hepion Pharmaceuticals Form 4 insider transactions real-time to watch when executives trade around data readouts.
Hepion Pharmaceuticals proxy statement executive compensation for details on option grants tied to trial success.
Hepion Pharmaceuticals earnings report filing analysis that connects 10-Q numbers to pipeline catalysts.
Hepion Pharmaceuticals 8-K material events explained so you can gauge trial announcements instantly.

Each section links to source PDFs and includes exportable tables for cash burn, share count, and Hepion Pharmaceuticals executive stock transactions Form 4 patterns. Make informed decisions faster—our AI summaries, real-time feeds, and complete coverage turn raw filings into actionable context.

06/30/2025 06:15 AM

Filing

[8-K] HEPION PHARMS INC Reports Material Event

Rhea-AI Summary

Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA) filed a Form 8-K to disclose the resignation of Chief Financial Officer and director John Brancaccio. His departure, attributed to personal reasons, is effective June 30, 2025. The filing, made pursuant to Item 5.02, notes that Kaouthar Lbiati signs as Interim CFO. No additional management changes, compensation details, or financial data were provided.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of Hepion Pharmaceuticals (HEPA)?

The current stock price of Hepion Pharmaceuticals (HEPA) is $0.0675 as of July 3, 2025.

What is the market cap of Hepion Pharmaceuticals (HEPA)?

The market cap of Hepion Pharmaceuticals (HEPA) is approximately 4.3M.

What is the primary focus of Hepion Pharmaceuticals Inc?

Hepion Pharmaceuticals Inc focuses on developing pleiotropic drug therapies for the treatment of chronic liver diseases, addressing multiple pathogenic pathways.

Which therapeutic areas does the company target?

The company targets chronic liver diseases including liver fibrosis, hepatocellular carcinoma, and chronic hepatitis, utilizing approaches like cyclophilin inhibition and antiviral therapy.

What distinguishes Hepion's drug development approach?

Hepion employs a multifaceted strategy by developing therapies that target several biochemical pathways simultaneously, offering a more comprehensive treatment approach compared to single-target therapies.

How does Hepion Pharmaceuticals generate revenue?

Revenue is primarily generated through milestone achievements in drug development and through strategic partnerships and collaborations within the biopharmaceutical sector.

What role do cyclophilin inhibitors play in their treatment strategy?

Cyclophilin inhibitors are central to Hepion's approach, designed to modulate multiple pathological pathways in liver diseases, thereby providing a broad-spectrum therapeutic benefit.

How does Hepion position itself in the competitive biopharmaceutical market?

By focusing on innovative, multi-target drug therapies for complex liver diseases, Hepion differentiates itself through its comprehensive research efforts and a clinical development strategy that addresses multiple disease mechanisms.

What is the significance of the company’s research and development efforts?

Their R&D efforts underline a commitment to understanding liver disease progression at a molecular level, paving the way for the development of therapies that are both scientifically robust and clinically impactful.

How can Hepion's strategy be described for investors looking for detailed company insights?

Investors can appreciate Hepion’s detailed approach to targeting chronic liver diseases through advanced drug therapies, characterized by a sophisticated understanding of disease mechanisms and robust clinical research.